NL-OMON38802已完成不适用
A SINGLE-CENTER, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 4-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETIC PROFILE OF FLURBIPROFEN FOLLOWING ADMINISTRATION OF 2 FLURBIPROFEN TRANSDERMAL FORMULATIONS COMPARED TO FROBEN® 50 MG AND YAKUBAN TAPE® IN HEALTHY SUBJECTS - Flurbiprofen transdermal patch relative bioavailability study
PRA International EDS0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male and female subjects
- •18-40 yrs, inclusive
- •BMI: 18.0-30.0 kg/m2, inclusive
- •non-smoking
- •light skin color
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
Systemic exposure bioequivalence study between two formulations of orally inhaled fluticasone propionate and salmeterol xinafoate....PACTR201508001220273Prosonix Limited60
已完成
不适用
Systemic exposure bioequivalence study between two formulations of orally inhaled fluticasone propionate and salmeterol xinafoate.PACTR201508001221356Prosonix Limited60
已完成
不适用
Systemic exposure bio equivalence study between 2 formulations of orally inhaled fluticasone propionate and salmeterol xinafoateRespiratoryHealthy subjects, intended disorder is asthmaPACTR201506001172164Prosonix Limited60
已完成
不适用
Systemic exposure bioequivalence study betwn two formulations of orally inhaled fluticasone propionate and salmeterol xinafoateRespiratoryHealthy subjects, intended disorder is asthmaPACTR201508001240411Prosonix Limited60
已完成
1 期
Systemic exposure bioequivalence study between two formulations of orally inhaled fluticasone propionate and salmeterol xinafoateHealthy subjects, intended disorder is asthmaPACTR201507001200173Prosonix Limited120